Bellicum Pharmaceuticals Valuation
Is BPXA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BPXA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BPXA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BPXA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BPXA?
Key metric: As BPXA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BPXA's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | US$1.51m |
| Market Cap | US$1.01m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.7x |
| Enterprise Value/EBITDA | -1.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BPXA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.5x | ||
SBH Sangui Biotech International | 3.8x | n/a | €419.8k |
ECX Epigenomics | 6.5x | n/a | €883.9k |
CNW co.don | 0.7x | n/a | €6.5m |
MDG1 Medigene | 3.1x | 16.1% | €23.3m |
BPXA Bellicum Pharmaceuticals | 0.7x | n/a | €1.0m |
Price-To-Sales vs Peers: BPXA is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (3.3x).
Price to Sales Ratio vs Industry
How does BPXA's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: BPXA is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Biotechs industry average (10.9x).
Price to Sales Ratio vs Fair Ratio
What is BPXA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BPXA's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Regeneron Pharmaceuticals
US$80.1b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$701.80
7D
-8.9%
1Y
-4.9%
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.40
7D
1.7%
1Y
-8.9%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.38
7D
-0.5%
1Y
-0.4%